CE and FDA Evidence in Chile: Value and Limits for ISP Registration

1. Key takeaways

Chile has no medical device mutual recognition arrangement with the European Union or the United States, and there is no formal fast track for reference-country approvals. The ISP reviews conformity under Chilean law, not the fact that another authority has already granted a clearance. However, CE technical documentation, FDA 510(k) and PMA letters, and notified body reports can be accepted as supporting evidence — particularly for the parts of Article 21 of DS 825/1998 that require scientific literature and effectiveness and safety studies for Class III and Class IV devices.

GRZAN’s conclusion fits in four words: an evidence base, not a passport. Foreign approvals strengthen the evidentiary record that the ISP reviews, but they neither replace Chilean requirements nor compress the statutory procedure. Budget them as components of a Chilean dossier, not as substitutes for one. In practice this changes how the marketing and regulatory teams talk: a CE mark supports the safety and performance argument inside the Chilean file, while the Chilean certificate itself must still be earned through the ISP procedure with its own documents, its own standards and its own queue.

2. Legal basis

• Regulation on the control of medical products and devices | Decreto Supremo N° 825, de 1998 | 21 August 1999 | Article 21: Class III requires supporting scientific literature together with the manufacturer’s effectiveness and safety studies; Class IV additionally requires studies in representative patient populations and research on the device’s inherent risks.
• Same instrument | Article 111, subparagraph c) of the Sanitary Code | quality control follows Chilean official standards (INN, approved by the Ministry of Health), and where none exist, the standards approved by the Ministry based on information from international organizations or foreign specialized bodies apply.
• Decree bringing HIV in vitro diagnostic reagents under control | Decreto Exento N° 41, de 2022 | 2022 | expressly establishes that conformity verification is carried out through documentary review, and that documentation from foreign sources may be accepted.
• Bringing the listed devices under the sanitary control regime of Article 111 | Decreto Exento N° 25, de 2026 | 19 March 2026 | conformity evaluation is benchmarked against NCh-ISO 16142-1/2, NCh-ISO 13485, NCh-ISO 14971 and product-specific standards.

3. Expert insights

Insight 1: Chile’s reliance mechanism exists only for medicines — do not extend it across product types.

The ISP once established an internal reliance procedure for biological products through Resolución Exenta N° E679/25, referencing high-health-authority regulators such as the FDA, EMA, MHRA, TGA and PMDA. That mechanism does not apply to medical devices under DS 825/1998. Transposing the medicines pathway onto devices is a recurring industry misjudgment, and it usually appears as a plan that waits for a reference-country approval before starting any Chilean work — losing months for nothing. The correct model is to run the Chilean dossier in parallel with any foreign approval process, letting each track feed evidence to the other.

Insight 2: the documentary review system determines the usability of foreign evidence.

The route of documentary review with acceptance of foreign-source documentation, established by Exempt Decree No. 41/2022, continues under the framework of Exempt Decree No. 25/2026. The ISP does not redo design verification; it assesses whether the evidence demonstrates conformity with the applicable Chilean standards. The same test report is worth far more under a documentary review system than under a laboratory resubmission system, which is why investment in evidence quality and mapping pays off directly. A report that is traceable, current and mapped to an NCh-ISO clause effectively does the reviewer’s cross-referencing work in advance.

Insight 3: foreign evidence must be translated into the language of Chilean standards — not simply submitted.

Article 111, subparagraph c) requires benchmarking against Chilean official standards. CE technical documentation is organized around European harmonized standards, and FDA submissions around United States recognized standards; both need an explicit mapping onto the NCh-ISO standards. GRZAN produces a one-page mapping table of foreign evidence against the essential principles of NCh-ISO 16142-1/2 in every project — the single most effective document for reducing rounds of technical queries.

Insight 4: the real value of CE and FDA material is fewer query rounds — not a shorter statutory procedure.

Foreign evidence can markedly reduce the ISP’s follow-up questions on safety and performance, but it does not change the submission procedure and does not change your position in the queue. Treating it as an accelerator and cutting documentation preparation time accordingly is the highest-risk misuse of these materials, because the deficiencies that follow land exactly where the removed work used to be. Communicate the same logic internally: foreign approvals buy review quality, not review speed, and the Chilean schedule must be built on the Chilean procedure’s own timeline.

4. Practical recommendations

1. Produce a mapping table of foreign evidence against NCh-ISO 16142-1/2, stating for each essential principle which document supports it.
2. Close the Chilean-side gaps: the ISO 13485 certificate, the risk management report, and Spanish labels and instructions for use cannot be replaced by foreign materials.
3. Retain originals and provenance of notified body reports and FDA letters, since documentary review depends on traceability.
4. Never promise the channel that CE marks bring fast certificates — it creates market expectations that the procedure cannot fulfill.
5. Watch standard versions: if the harmonized standards cited on a CE certificate have since been updated, explain the relationship to the current NCh versions.

5. Verification checklist

• □ It has been confirmed that Chile has no reference-country mutual recognition channel for devices
• □ A mapping table between foreign evidence and NCh-ISO 16142-1/2 has been established
• □ Chile-specific documentation (ISO 13485, risk management, Spanish labels and instructions for use) has been completed
• □ Originals and provenance of notified body reports and FDA letters have been retained
• □ The relationship between cited standard versions and current NCh versions has been checked

Regulatory information verified as of 29 October 2026.

GRZAN supports manufacturers entering the Chilean market with ISP registration pathways and classification strategy, including evidence mapping onto NCh-ISO standards and dossier gap analysis. For a feasibility assessment of your specific product, contact the GRZAN regulatory team at info@grzanglobal.com.